BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path

TLDR:

• BYSI Stock Surges 5.28%: Plinabulin Shows Strong Survival Benefit in NSCLC

• BeyondSpring’s Plinabulin Data Boosts NSCLC Treatment Hope, Stock Gains 5.3

• Plinabulin’s Phase 3 Results Strengthen BYSI’s Case for Global NSCLC Approval

• BYSI Stock Jumps 5.28% After Promising NSCLC Trial Results at ESMO Asia
• BeyondSpring Shows Survival Benefit with Plinabulin in NSCLC, Stock Soars

BeyondSpring Inc. (BYSI) saw a notable increase in its stock price, surging by 5.28%, after announcing promising results from its Phase 3 DUBLIN-3 trial.

BeyondSpring Inc., BYSI

The trial evaluated the combination of Plinabulin and docetaxel against docetaxel alone for treating second- and third-line EGFR wild-type non-small cell lung cancer (NSCLC). These results, presented at ESMO Asia 2025, revealed a significant survival benefit for patients using the Plinabulin combination, boosting market confidence and increasing the company’s stock to $2.1150.

Strong Results from the DUBLIN-3 Trial’s Asian Subset

In the Phase 3 DUBLIN-3 trial, the combination of Plinabulin and docetaxel showed a median overall survival (OS) of 10.8 months, compared to 8.8 months with docetaxel alone. The combination’s survival benefi-t was statistically significant with a hazard ratio (HR) of 0.81, meeting the primary endpoint (p=0.0426). This result supports the potential of Plinabulin to improve survival rates for patients with EGFR wild-type NSCLC, signaling a breakthrough in treatment options for this challenging condition.

Further analysis of the non-squamous subgroup showed even more favorable results. For this group, the hazard ratio was 0.69, which translates to a three-month median OS benefit (p=0.0064). These findings reinforce the targeted mechanism of Plinabulin, highlighting its potential to improve survival, especially for patients whose disease biology aligns with the drug’s immune-modulating properties.

Plinabulin also demonstrated a clear safety advantage over docetaxel. The combination therapy significantly reduced the incidence of docetaxel-induced grade 4 neutropenia, with only 3.9% of patients affected compared to 26.5% in the docetaxel-only group (p<0.0001). This reduction in neutropenia allows for better chemotherapy tolerability, crucial for maintaining treatment effectiveness and patient quality of life.

Plinabulin’s Mechanism and Future Prospects

Plinabulin, a first-in-class immune-modulating agent, works by targeting dendritic-cell maturation and tumor vasculature. The drug has already shown durable anti-cancer benefits and good tolerability in over 700 patients across various clinical studies. The combination of Plinabulin and docetaxel offers a novel treatment approach, improving survival rates while reducing chemotherapy-induced side effects.

BeyondSpring’s management is confident that the promising data from the DUBLIN-3 trial will support Plinabulin’s global registration for NSCLC. The company plans to advance Plinabulin through a global Phase 3 confirmatory study, aiming to expand its use beyond the Asian market. This study will be a critical step toward positioning Plinabulin as a standard-of-care treatment for NSCLC, especially for patients with EGFR wild-type mutations.

The post BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path appeared first on CoinCentral.